loading
Viking Therapeutics Inc stock is traded at $29.35, with a volume of 2.01M. It is down -1.97% in the last 24 hours and down -25.29% over the past month. Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$29.96
Open:
$29.45
24h Volume:
2.01M
Relative Volume:
0.51
Market Cap:
$3.30B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-31.56
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-12.33%
1M Performance:
-25.29%
6M Performance:
-49.70%
1Y Performance:
-7.42%
1-Day Range:
Value
$29.16
$30.30
1-Week Range:
Value
$29.08
$33.40
52-Week Range:
Value
$29.08
$99.41

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name
Name
Viking Therapeutics Inc
Name
Phone
858-704-4660
Name
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Name
Employee
34
Name
Twitter
@viking_vktx
Name
Next Earnings Date
2024-10-23
Name
Latest SEC Filings
Name
VKTX's Discussions on Twitter

Compare VKTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VKTX
Viking Therapeutics Inc
29.35 3.30B 0 -99.15M -74.25M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
451.43 117.23B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
663.70 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
648.80 39.35B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
265.42 34.31B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
112.33 27.21B 3.30B -501.07M 1.03B -2.1146

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-07-25 Initiated Citigroup Neutral
Dec-02-24 Initiated Piper Sandler Overweight
Nov-22-24 Initiated B. Riley Securities Buy
Nov-04-24 Reiterated H.C. Wainwright Buy
Sep-11-24 Initiated JP Morgan Overweight
Jun-27-24 Initiated Morgan Stanley Overweight
May-16-24 Upgrade Raymond James Outperform → Strong Buy
Mar-26-24 Reiterated Oppenheimer Outperform
Mar-07-24 Initiated Jefferies Buy
Feb-28-24 Reiterated Oppenheimer Outperform
May-31-23 Resumed ROTH MKM Buy
Mar-28-23 Reiterated Maxim Group Buy
Mar-17-23 Initiated Stifel Buy
Jul-29-21 Resumed BTIG Research Buy
May-25-21 Downgrade Raymond James Strong Buy → Outperform
Jun-05-20 Initiated BMO Capital Markets Outperform
May-05-20 Initiated Chardan Capital Markets Buy
May-01-20 Initiated BTIG Research Buy
Jul-16-19 Initiated Oppenheimer Outperform
Jun-25-19 Initiated Stifel Buy
Mar-29-19 Upgrade SVB Leerink Mkt Perform → Outperform
Mar-14-19 Reiterated Maxim Group Buy
Feb-22-19 Initiated SVB Leerink Mkt Perform
Dec-12-18 Initiated B. Riley FBR Buy
Nov-19-18 Upgrade Raymond James Outperform → Strong Buy
Sep-18-18 Reiterated H.C. Wainwright Buy
Sep-18-18 Reiterated Maxim Group Buy
Sep-18-18 Reiterated Raymond James Outperform
Jul-20-18 Initiated SunTrust Buy
Jun-28-18 Initiated Raymond James Outperform
Jun-01-18 Reiterated Laidlaw Buy
May-31-18 Reiterated Maxim Group Buy
Mar-26-18 Resumed H.C. Wainwright Buy
Nov-28-17 Reiterated Maxim Group Buy
Nov-21-17 Initiated ROTH Capital Buy
View All

Viking Therapeutics Inc Stock (VKTX) Latest News

pulisher
03:02 AM

Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 1.2%Should You Sell? - MarketBeat

03:02 AM
pulisher
Feb 11, 2025

Why Viking Therapeutics Inc. (VKTX) Went Down on Monday - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today - Benzinga

Feb 11, 2025
pulisher
Feb 10, 2025

Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today - The Motley Fool

Feb 10, 2025
pulisher
Feb 10, 2025

2 Stocks to Buy With Less Than $40 - Yahoo Finance

Feb 10, 2025
pulisher
Feb 09, 2025

Viking Therapeutics Stock Price Forecast for 2025 - Markets.com

Feb 09, 2025
pulisher
Feb 09, 2025

Viking Therapeutics started at neutral by Citi - MSN

Feb 09, 2025
pulisher
Feb 09, 2025

How to Take Advantage of moves in (VKTX) - Stock Traders Daily

Feb 09, 2025
pulisher
Feb 09, 2025

Raymond James Boosts Viking Therapeutics (NASDAQ:VKTX) Price Target to $125.00 - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

Down 65%, Is Viking Therapeutics Stock a Buy on the Dip? - sharewise

Feb 08, 2025
pulisher
Feb 08, 2025

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10% - MSN

Feb 08, 2025
pulisher
Feb 08, 2025

Viking Therapeutics price target lowered to $96 from $109 at B. Riley - Yahoo Finance

Feb 08, 2025
pulisher
Feb 08, 2025

2 Stocks That Could Soar Again in 2025 - Yahoo Finance

Feb 08, 2025
pulisher
Feb 07, 2025

Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year - MSN

Feb 07, 2025
pulisher
Feb 07, 2025

B. Riley Adjusts Price Target on Viking Therapeutics to $96 From $109, Keeps Buy Rating - Marketscreener.com

Feb 07, 2025
pulisher
Feb 07, 2025

Citigroup Initiates Viking Therapeutics at Neutral With $38 Price Target -February 07, 2025 at 08:52 am EST - Marketscreener.com

Feb 07, 2025
pulisher
Feb 07, 2025

Truist Securities Adjusts Viking Therapeutics Price Target to $95 From $120, Maintains Buy Rating - Marketscreener.com

Feb 07, 2025
pulisher
Feb 07, 2025

Citigroup initiated coverage on Viking Therapeutics with a new price target - Quantisnow

Feb 07, 2025
pulisher
Feb 06, 2025

Viking Therapeutics Reports Strong Trials and Financial Health - TipRanks

Feb 06, 2025
pulisher
Feb 06, 2025

Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why. - Yahoo

Feb 06, 2025
pulisher
Feb 06, 2025

Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Has the Bubble Burst for Viking Therapeutics Stock? - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Viking Therapeutics price target raised to $125 from $122 at Raymond James - TipRanks

Feb 06, 2025
pulisher
Feb 06, 2025

Viking Therapeutics Inc (VKTX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance

Feb 06, 2025
pulisher
Feb 05, 2025

Viking Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics Reports Positive 2024 Financials and Clinical Progress - TipRanks

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why. - Yahoo! Voices

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics : February 2025 Corporate Presentation - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

VIKING THERAPEUTICS Earnings Results: $VKTX Reports Quarterly Earnings - Nasdaq

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates - Benzinga

Feb 05, 2025
pulisher
Feb 05, 2025

Viking stock slides 8% following Q4 report, pipeline update - Seeking Alpha

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Fin - GuruFocus.com

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics, Inc. (VKTX): One of January’s Biggest Losers - Insider Monkey

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics reports Q4 EPS (32c), consensus (27c) - TipRanks

Feb 05, 2025
pulisher
Feb 05, 2025

Viking's Obesity Drug Achieves 14.7% Weight Loss, Phase 3 Launch Set for Q2 - StockTitan

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - Yahoo Finance

Feb 05, 2025
pulisher
Feb 05, 2025

BlackRock, Inc. Expands Stake in Viking Therapeutics Inc - GuruFocus.com

Feb 05, 2025
pulisher
Feb 05, 2025

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Prediction: This Pharma Stock Will Be the Best Performer in 2025 - 24/7 Wall St.

Feb 05, 2025
pulisher
Feb 05, 2025

Why Does Jim Cramer Prefer Eli Lilly (LLY) Over Viking Therapeutics? - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring - Seeking Alpha

Feb 05, 2025
pulisher
Feb 05, 2025

Can Viking Touch The $100 Mark? - RTTNews

Feb 05, 2025
pulisher
Feb 04, 2025

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Janney Montgomery Scott LLC - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by U.S. Capital Wealth Advisors LLC - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Brokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) PT at $106.75 - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Institute for Wealth Management LLC. - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

Viking Therapeutics (VKTX) to Release Quarterly Earnings on Wednesday - MarketBeat

Feb 03, 2025
pulisher
Feb 02, 2025

Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy? - MSN

Feb 02, 2025

Viking Therapeutics Inc Stock (VKTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$80.11
price up icon 0.20%
$32.30
price up icon 0.22%
$4.69
price up icon 5.15%
$367.87
price up icon 4.07%
biotechnology ONC
$223.09
price up icon 0.81%
$112.58
price down icon 1.68%
Cap:     |  Volume (24h):